E-LIB Suche - Ergebnisse für: Bordogna, Walter

1

Updated efficacy and safety of entrectinib in NTRK fusion-p..:

Cho, Byoung Chul ; Chiu, Chao-Hua ; Massarelli, Erminia...
Lung Cancer. 188 (2024) - p. 107442 , 2024

Link: https://doi.org/10.1016/..

2

Concordance Between Tissue ALK Detection by Immunohistochem..:

Noé, Johannes ; Bordogna, Walter ; Archer, Venice...
JTO Clinical and Research Reports. 3 (2022) 7 - p. 100341 , 2022

Link: https://doi.org/10.1016/..

3

Circulating Cell-free DNA as a Prognostic Biomarker in Pati..:

Dziadziuszko, Rafal ; Peters, Solange ; Mok, Tony...
Clinical Cancer Research. 28 (2022) 9 - p. 1800-1808 , 2022

Link: https://doi.org/10.1158/..

4

Pharmacometric analyses of alectinib to facilitate approval..:

Hsu, Joy C. ; Jaminion, Felix ; Guerini, Elena...
CPT: Pharmacometrics & Systems Pharmacology. 10 (2021) 11 - p. 1357-1370 , 2021

Link: https://doi.org/10.1002/..

5

Optimized Alectinib Dose Regimen for Treatment of Patients ..:

Frey, Nicolas ; Bordogna, Walter ; Balas, Bogdana...
Clinical Pharmacology & Therapeutics. 110 (2021) 5 - p. 1162-1163 , 2021

Link: https://doi.org/10.1002/..

6

ALK Mutation Status Before and After Alectinib Treatment in..:

Noé, Johannes ; Lovejoy, Alex ; Ou, Sai-Hong Ignatius...
Journal of Thoracic Oncology. 15 (2020) 4 - p. 601-608 , 2020

Link: https://doi.org/10.1016/..

7

Pooled overall survival and safety data from the pivotal ph..:

Ou, Sai-Hong Ignatius ; Gadgeel, Shirish M. ; Barlesi, Fabrice...
Lung Cancer. 139 (2020) - p. 22-27 , 2020

Link: https://doi.org/10.1016/..

8

Updated Efficacy and Safety Data and Impact of the EML4-ALK..:

Camidge, D. Ross ; Dziadziuszko, Rafal ; Peters, Solange...
Journal of Thoracic Oncology. 14 (2019) 7 - p. 1233-1243 , 2019

Link: https://doi.org/10.1016/..

9

Patient-reported outcomes in a phase II, North American stu..:

Ou, Sai-Hong Ignatius ; Socinski, Mark A ; Gadgeel, Shirish...
ESMO Open. 3 (2018) 5 - p. e000364 , 2018

Link: https://doi.org/10.1136/..

10

Exposure–response analysis of alectinib in crizotinib-resis..:

Morcos, Peter N. ; Nueesch, Eveline ; Jaminion, Felix...
Cancer Chemotherapy and Pharmacology. 82 (2018) 1 - p. 129-138 , 2018

Link: https://doi.org/10.1007/..

11

Pooled Systemic Efficacy and Safety Data from the Pivotal P..:

Yang, James Chih-Hsin ; Ou, Sai-Hong Ignatius ; De Petris, Luigi...
Journal of Thoracic Oncology. 12 (2017) 10 - p. 1552-1560 , 2017

Link: https://doi.org/10.1016/..

12

MA07.02 Updated Efficacy and Safety Data from the Phase 2 N..:

Camidge, D. Ross ; Gadgeel, Shirish ; Ou, Sai-Hong...
Journal of Thoracic Oncology. 12 (2017) 1 - p. S378 , 2017

Link: https://doi.org/10.1016/..

13

P3.02a-016 Pooled Efficacy and Safety Data from Two Phase I..:

Chih-Hsin Yang, James ; Ou, Sai-Hong ; De Petris, Luigi...
Journal of Thoracic Oncology. 12 (2017) 1 - p. S1170-S1171 , 2017

Link: https://doi.org/10.1016/..

14

MA07.01 Updated Pooled Analysis of CNS Endpoints in Two Pha..:

Ignatius Ou, Sai-Hong ; Gandhi, Leena ; Shaw, Alice...
Journal of Thoracic Oncology. 12 (2017) 1 - p. S377 , 2017

Link: https://doi.org/10.1016/..

15

Efficacy of alectinib in central nervous system metastases ..:

Gandhi, Leena ; Ou, Sai-Hong Ignatius ; Shaw, Alice T....
European Journal of Cancer. 82 (2017) - p. 27-33 , 2017

Link: https://doi.org/10.1016/..